Eli Lilly and Company (NYSE:LLY) is among the stocks with the best earnings growth for the next 5 years. On January 14, BMO Capital reaffirmed an ‘Outperform’ rating on Eli Lilly and Company (NYSE:LLY) with a price target of $1,200. Matching the consensus 1-year median target price, the stock has an upside potential of 16.36%. The firm remains confident in the company’s solid leadership position in the obesity treatment space and beyond for 2026 and the years ahead.
BMO Capital pointed out that growth and certainty for the company’s incretin business is backed by broadening access, the expected launch of orforglipron, and the company’s growing portfolio. While maintaining its leadership in the obesity market, Eli Lilly and Company (NYSE:LLY) also has a solid presence in other disease areas, particularly Lp(a), which contributes to its long-term growth outlook, the firm added.
Pixabay/Public Domain
Two days earlier, Eli Lilly and Company (NYSE:LLY) announced a partnership with NVIDIA to develop an AI co-innovation lab focused on pharmaceutical research. The leading entities plan to invest up to $1 billion in talent, infrastructure, and computing resources over a period of five years.
Eli Lilly and Company (NYSE:LLY) is an Indiana-based company that discovers, develops, and markets human pharmaceuticals. Founded in 1876, the company is committed to improving people’s lives around the globe.
While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
